Dr. Congying Xie, MD, Ph.D

Title:

Vice President of the First Affiliated Hospital of Wenzhou Medical University;

Dean of Wenzhou Key Laboratory of Radiotherapy and Translational Research

Institution:

The First Affiliated Hospital of Wenzhou Medical University

Education Background

· 1992.09–1997.07: MD in Clinical Medicine, Wenzhou Medical College

· 2001.03–2002.03: Visiting Scholar, Department of Radiation Oncology, Fudan University Shanghai Cancer Center

· 2002.09–2005.07: MS in Radiation Oncology, Wenzhou Medical College

· 2009.03–2012.10: Ph.D. in Radiation Oncology, Huazhong University of Science and Technology

· 2009.05–2009.11: Visiting Scholar, Department of Radiation Oncology, Michigan University Hospital Cancer Center

Professional Experience

· 1997.08–2001.03: Resident Physician, Radiation Oncology Department, 1st Affiliated Hospital of Wenzhou Medical College

· 2001.03–2007.10: Attending Physician, Radiation Oncology Department, 1st Affiliated Hospital of Wenzhou Medical College

· 2007.10–2012.10: Vice Director, Department of Radiation and Medical Oncology, 1st Affiliated Hospital of Wenzhou Medical College

· 2012.10–2020.01: Director, Department of Radiation and Medical Oncology, 1st Affiliated Hospital of Wenzhou Medical University

· 2020.01–2023.12: Vice President, Second Affiliated Hospital of Wenzhou Medical University

· 2024.01–Present: Vice President, 1st Affiliated Hospital of Wenzhou Medical University

Clinical and Research Interests

· Innovative cancer prevention and therapy techniques

· Radiomics and image-guided radiotherapy technology

· Early diagnosis and detection of cancer

· Radioprotection

Committee Services

1. Board Member, Chinese Society of Clinical Oncology

2. Vice Chairman, Chinese Society of Biomedical Engineering Precision Radiotherapy Technology Branch

3. Vice Chairman, Radiation Oncology Committee of Zhejiang Medical Association

4. Standing Committee Member, Youth Council of China Anti-Cancer Association

5. Chairman, Thoracic Tumor Committee of Zhejiang Medical Association

6. Chairman, Biotherapy Committee of Zhejiang Anti-Cancer Association

7. Chairman, Chemotherapy and Biotherapy Committee of Zhejiang Medical Association

8. Chairman, Cancer Radiotherapy and Chemotherapy Branch of Wenzhou Medical Association

9. Standing Committee Member, Tumor Radiation Protection Special Committee, China Anti-Cancer Association

Research Funding (Selected Projects)

1. 2024–2026: Pioneer and Leading Goose R&D Program of Zhejiang, "New technical research for early diagnosis of lung cancer through cross-modal fusion with exosome multiomics based on miRNA isoform and AI," 4.5M RMB (PI)

2. 2023–2026: China National Nature Science Foundation, "HPV E7 protein promotes radiation-induced lung injury," 0.52M RMB (PI)

3. 2020–2023: Key Project of Zhejiang Department of Science and Technology, "Identification of circulating diagnostic markers for early lung cancer," 3M RMB (PI)

4. 2020–2022: Wenzhou Science and Technology Bureau, "Study on the effect of specific removal of exocrine from lung cancer on immunotherapy," 600K RMB (PI)

5. Multiple additional projects from Zhejiang Province and Wenzhou Science and Technology Bureau focusing on lung cancer, radiotherapy, and diagnostic technologies.

Selected Publications

1. Yin H#, Hu X#, Xie C#, et al. A T-Cell Inspired Sonoporation System Enhances Low-Dose X-Ray-Mediated Pyroptosis and Radioimmunotherapy Efficacy. Advanced Materials, 2024, 2401384.

2. Yin H#, Xie C#, Zuo Z, et al. A CTL-Inspired Killing System Using Ultralow-Dose Chemical Drugs to Induce Pyroptosis-Mediated Antitumor Immune Function. Advanced Materials, 2023, 2309839.

3. Xie C#, Chen X#, Chen Y#, et al. Mutual Communication Between Radiosensitive and Radioresistant Esophageal Cancer Cells Modulates Radiosensitivity. Cell Death & Disease, 2023, 14:846.

4. Zuo Z#, Yin H#, Zhang Y, Xie C, et al. A Cytotoxic T Cell Inspired Oncolytic Nanosystem Promotes Lytic Cell Death by Lipid Peroxidation and Elicits Antitumor Immune Responses. Nature Communications, 2023, 14:5456.

5. Wang S, Bei Y, Tian Q, et al., Xie C*. PFKFB4 Facilitates Palbociclib Resistance in Oestrogen Receptor-Positive Breast Cancer by Enhancing Stemness. Cell Proliferation, 2023, 56(1):e13337.

6. Yao Q, Ye J, Chen Y, et al., Xie C*. Modulation of Glucose Metabolism through Macrophage-Membrane-Coated Metal-Organic Framework Nanoparticles for Triple-Negative Breast Cancer Therapy. Chemical Engineering Journal, 2023, 148069.

(List continues with over 50 publications in top journals such as Nature Communications, Advanced Materials, Cell Proliferation, and more.)

Awards and Honors

1. 2021: China Zhejiang Province Innovation Award on Health and Medicine – Third Prize for technical innovation in early diagnosis and accurate treatment of thoracic tumors.

2. 2017: China Zhejiang Province Innovation Award on Health and Medicine – Third Prize for optimization of chest tumor radiotherapy techniques.

3. 2013: Zhejiang Province Science and Technology Award – Third Prize for studies on parotid protection in NPC treatment.

Patents (Selected)

1. Lung Adenocarcinoma Detection Kit: ZL202111173417.4 (PI)

2. Kits and Systems for Low-Dose CT in Screening Lung Cancer: ZL202210508228.6 (PI)

3. Vision Fixation Device for Ocular Tumor Radiotherapy: ZL201220270789.9 (Co-Inventor)

(Complete list includes additional patents on radiotherapy devices and diagnostic technologies.)

Contact Information:

Email: wzxiecongying@163.com

Phone: +86-13867711881